TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21211337
Drug: Intratympanic methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic methylprednisolone injection (62.5 mg/ml) infused at a rate of 10 microl/h for 14 days
Study: 12742294
Drug: Bucindolol (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bucindolol (a beta-blocker)
Study: 14564594
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of 8 ml of physiological saline after spinal hyperbaric tetracaine
Study: 14564594
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of 8 ml of physiological saline after spinal isobaric tetracaine
Study: 14564594
Drug: Spinal hyperbaric
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal hyperbaric tetracaine without epidural injection
Study: 14564594
Drug: Spinal isobaric
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal isobaric tetracaine without epidural injection
Study: 27448700
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity atorvastatin (40 mg/day)
Study: 27448700
Drug: Moderate intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate intensity atorvastatin (20 mg/day)
Study: 10198862
Drug: Asymmetric corneal
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asymmetric corneal tunnel incisions with an L‐shaped entrance and a concave exit
Study: 2184874
Drug: Sensory integration
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensory integration (SI) sessions, about 13 weekly sessions, each of 1 hour duration
Study: 385456
Drug: Hydrocortisate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisate treatment
Study: 21917766
Drug: ELND005 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELND005 250 mg
Study: 19074463
Drug: L-T(4) withdrawal
Normalized name: (T,G)-A-L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-T(4) withdrawal (37 days); 21 patients received (131)I (2.02+/‐0.22 GBq; 54.6+/‐5.9 mCi)
Study: 19074463
Drug: rhTSH stimulation;
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTSH stimulation; 21 patients received (131)I (1.97+/‐0.18 GBq; 53.2+/‐4.9 mCi) 24 h after rhTSH (0.9 mg)
Study: 16696817
Drug: Renzapride 2
Normalized name: Renzapride
DrugBank: Renzapride (DB04917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renzapride 2 mg o.d.
Study: 20163375
Drug: Renzapride 2
Normalized name: Renzapride
DrugBank: Renzapride (DB04917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renzapride 2 mg b.d.
Study: 11737382
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg per day)
Study: 9764979
Drug: IFN-alpha treatment
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha treatment for 24 weeks
Study: 30058418
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (VitC) treatment group
Study: 30058418
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (VitC) non-treatment group
Study: 9377616
Drug: Voglibose 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose 0.3 mg
Study: 8385844
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (two doses + booster)
Study: 8385844
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (booster dose)
Study: 31228383
Drug: Complex non-drug
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex non-drug programs including exercise therapy, drinking balneotherapy, multivitamins, vibrotherapy, chromotherapy, melody therapy, aromatherapy, aeroionotherapy
Study: 25420207
Drug: Rasagiline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline (1 or 2 mg/d)
Study: 21663680
Drug: High calorie
Normalized name: High calorie formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calorie high protein supplement for forty days in addition to their diet of choice
Study: 16836625
Drug: Disease management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease management program including screening, patient education, drug therapy with paroxetine, and supportive contacts.
Study: 16836625
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (control group) where general practitioners were blind to the screening results and treatment was not restricted.
Study: 15523172
Drug: Heparin group
Normalized name: Heparin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin group (20-ml saline-flush followed by 2 ml of 1,000 U/ml heparin-lock)
Study: 15523172
Drug: Saline group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline group (20-ml saline-flush once a day for each lumen)
Study: 11199329
Drug: CD14 CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD14 CC genotype
Study: 11199329
Drug: IL-6-174 CC
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6-174 CC genotype
Study: 9261525
Drug: Granisetron, dexamethasone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron, dexamethasone, and their combination (exact dosages and duration not specified)
Study: 8392825
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg granisetron
Study: 10882331
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg granisetron
Study: 8392825
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg granisetron
Study: 3080282
Drug: Misoprostol 100
Normalized name: MISOPROSTOL 100MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 100 micrograms qid (without antacid)
Study: 3080282
Drug: Misoprostol 50
Normalized name: diclofenac-misoprostol 50 mg-200 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 50 micrograms qid (with limited antacid)
Study: 3080282
Drug: Misoprostol 200
Normalized name: MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 200 micrograms qid (with limited antacid)
Study: 25906974
Drug: Personalized dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized dosing strategy
Study: 25906974
Drug: Standardized dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized dosing strategy
Study: 17019663
Drug: Early warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early warfarin administration (12 hr after TCC placement) with ticlopidine 250 mg/die
Study: 17019663
Drug: Warfarin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin administration after the first thrombosis/malfunction episode with ticlopidine 250 mg/die
Study: 10735893
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy (Hfx RT) with concurrent low-dose daily cisplatin (6 mg/m²)
Study: 10735893
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy (Hfx RT) alone
Study: 2412041
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg twice daily for 4 weeks
Study: 2412041
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg twice daily for 4 weeks
Study: 26749220
Drug: Huoxue-Tongluo lyophilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huoxue-Tongluo lyophilized powder for injection (HTLPI) 3 g
Study: 26749220
Drug: Huoxue-Tongluo lyophilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huoxue-Tongluo lyophilized powder for injection (HTLPI) 6 g (multiple-dose, once daily)
Study: 26749220
Drug: Huoxue-Tongluo lyophilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huoxue-Tongluo lyophilized powder for injection (HTLPI) 9 g
Study: 26749220
Drug: Huoxue-Tongluo lyophilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huoxue-Tongluo lyophilized powder for injection (HTLPI) 6 g
Study: 26749220
Drug: Huoxue-Tongluo lyophilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huoxue-Tongluo lyophilized powder for injection (HTLPI)
Study: 24466245
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) 25 mg/kg
Study: 24466245
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) 50 mg/kg
Study: 23143762
Drug: No local
Approvals — FDA: no, EMA: no, PMDA: no
Description: No local therapy (noL)
Study: 11591234
Drug: MCT meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT meal (15 g fat)
Study: 11591234
Drug: Linoleate meal
Normalized name: linoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linoleate meal (50 g fat)
Study: 7520210
Drug: Chlorthalidone (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (12.5 and 25 mg/day)
Study: 31948507
Drug: Specific program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific program components used in treatment procedures
Study: 31021980
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) 35 mg orally twice a day for three months, in addition to conventional treatments for angina.
Study: 31021980
Drug: Conventional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatments for angina only.
Study: 28499583
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (epirubicin 60 mg/m2 per day plus ifosfamide 3 g/m2 per day, repeated every 21 days)
Study: 28499583
Drug: Histotype-tailored chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histotype-tailored chemotherapy (various regimens based on histological subtype)
Study: 28499583
Drug: Histotype-tailored chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histotype-tailored chemotherapy
Study: 24183196
Drug: Warmed irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed irrigation solution at 32°C ± 2°C (89.6°F ± 3.6°F)
Study: 24183196
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature irrigation solution (Control)
Study: 17399635
Drug: Corticosteroids (intermediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (intermediate doses of 50-210 mg dexamethasone equivalent)
Study: 17399635
Drug: Corticosteroids (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (lower doses up to 8 mg)
Study: 17399635
Drug: Corticosteroids (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (higher doses 236-2850 mg)
Study: 2008948
Drug: Midazolam 0.4-5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.4-5.0 mg.kg-1
Study: 2008948
Drug: Midazolam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.3 mg.kg-1
Study: 2008948
Drug: Midazolam 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 1.0 mg.kg-1 or greater
Study: 2008948
Drug: Midazolam 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 2.0 mg.kg-1 or greater
Study: 6800869
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (low-dose, 375 mg/day)
Study: 6800869
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (high-dose, 750 mg/day)
Study: 6800869
Drug: High-dose chenodeoxycholic
Normalized name: chenodeoxycholate
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chenodeoxycholic acid
Study: 6800869
Drug: High-dose chenodeoxycholic
Normalized name: chenodeoxycholate
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chenodeoxycholic acid (women)
Study: 223950
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid therapy
Study: 31088090
Drug: Dexmedetomidine (DXM)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DXM) 0.5 mcg/kg with 0.5% ropivacaine 20 mL
Study: 31088090
Drug: Dexamethasone (DXA)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXA) 8 mg with 0.5% ropivacaine 20 mL
Study: 29295513
Drug: 10 µg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg/day vitD3
Study: 29295513
Drug: 10 µg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg/day 25OH‐D3
Study: 29295513
Drug: 10 µg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg/day vitD2
Study: 22658512
Drug: Early salvage
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early salvage hormonal therapy (PSA≤10 ng/mL and absent distant metastases)
Study: 22658512
Drug: Late salvage
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late salvage hormonal therapy (PSA>10 ng/mL and absent distant metastases)
Study: 22658512
Drug: Late salvage
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late salvage hormonal therapy (distant metastases)
Study: 2666080
Drug: Effervescent tablets
Normalized name: Hydralyte Effervescent Tablets Berry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent tablets A (161 mg daily)
Study: 2666080
Drug: Effervescent tablets
Normalized name: Hydralyte Effervescent Tablets Berry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent tablets A* (161 mg daily)
Study: 2666080
Drug: Proprietary iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprietary iron preparation B (150 mg daily)
Study: 909253
Drug: Euthyscope treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euthyscope treatment
Study: 30097995
Drug: Insulin Degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin Degludec
Study: 29713962
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine U100
Study: 18834692
Drug: Treatment seekers
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment seekers
Study: 14993771
Drug: Nicorandil (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (4 mg iv and 4 mg ic before reperfusion, followed by continuous infusion at 4 mg/h for 24 h)
Study: 14993771
Drug: Magnesium (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (10 mmol iv before reperfusion, followed by continuous infusion at 0.4 mmol/h for 24 h)
Study: 11782040
Drug: Refined estimator
Normalized name: refined almond oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined estimator for the variance of the treatment effect estimator
Study: 11406840
Drug: Proposed test
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed test for overall treatment effect
Study: 9293679
Drug: 10% sucralfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sucralfate in sorbolene cream
Study: 9300326
Drug: SNX‐111 (neuron-specific,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNX‐111 (neuron-specific, N-type, voltage-sensitive calcium channel blocker)
Study: 2527274
Drug: rHBV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHBV vaccine (2 micrograms)
Study: 2527274
Drug: rHBV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHBV vaccine (5 micrograms)
Study: 2527274
Drug: rHBV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHBV vaccine (10 micrograms)
Study: 2527274
Drug: rHBV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHBV vaccine (20 micrograms)
Study: 2527274
Drug: plasma-derived hepatitis
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: plasma-derived hepatitis B virus vaccine (Hevac B Pasteur)
Study: 2527274
Drug: rHBV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHBV vaccine (10 and 20 micrograms)
Study: 2527274
Drug: rHBV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHBV vaccine
Study: 1106927
Drug: Transfer factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer factor therapy (equivalent to 2‐1 X 10(8) leucocytes)
Study: 26598475
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (RISP, LI, VAL)
Study: 15282428
Drug: ACIST Injection
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACIST Injection System (automated contrast injection)
Study: 15282428
Drug: Manual injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual injection (control group)
Study: 11302274
Drug: Applied Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied Family Management (AFM) including 1 year of behavioral family therapy plus support groups for 2 years
Study: 11302274
Drug: Supportive Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive Family Management (SFM) including monthly support groups for 2 years
Study: 11302274
Drug: Standard, low,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard, low, targeted neuroleptic dosage strategies
Study: 11302274
Drug: Time-limited behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-limited behavioral family therapy added to monthly support groups
Study: 9531235
Drug: Hospital-based smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-based smoking intervention consisting of a 15-minute bedside counseling session, written self-help material, a chart prompt for physicians, and up to 3 weekly counseling telephone calls after discharge.
Study: 29735284
Drug: Music listening
Normalized name: Listerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music listening intervention (60 minutes, twice a day, over three days)
Study: 19892350
Drug: Astaxanthin 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin 6 mg/day
Study: 19892350
Drug: Astaxanthin 12
Normalized name: astaxanthin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin 12 mg/day
Study: 19892350
Drug: Astaxanthin 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin 18 mg/day
Study: 12464836
Drug: Topical aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aqueous cream
Study: 10499484
Drug: Cholylsarcosine 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholylsarcosine 6 g/day
Study: 10499484
Drug: Cholylsarcosine 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholylsarcosine 12 g/day
Study: 27668927
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of daily living (Katz ADL)
Study: 19108877
Drug: Cisplatin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (50 mg/m(2)) and Doxorubicin (45 mg/m(2))
Study: 19108877
Drug: Cisplatin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (50 mg/m(2)), Doxorubicin (45 mg/m(2)), and Paclitaxel (160 mg/m(2))
Study: 11824175
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of porcine secretin
Study: 7992097
Drug: standard hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard hydroxyurea chemotherapy
Study: 2662999
Drug: Exogenous natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous natural surfactant treatment
Study: 2662999
Drug: Prophylactic surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic surfactant treatment at birth
Study: 23060621
Drug: Glaucoma medications
Normalized name: ANTIGLAUCOMA MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glaucoma medications (various types including prostaglandins, β blockers, and carbonic anhydrase inhibitors)
Study: 23060621
Drug: Glaucoma medications
Normalized name: ANTIGLAUCOMA MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glaucoma medications (various types)
Study: 21510905
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral supplement containing vitamin A (7000 ug retinol equivalents)
Study: 21510905
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral supplement containing beta-carotene (42 mg, or 7000 ug retinol equivalents)
Study: 15488350
Drug: Continuous estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous estrogen and progesterone in combination (Group III)
Study: 15488350
Drug: Cyclic estrogen
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic estrogen and progesterone combination (Group IV)
Study: 9437560
Drug: DMPA (Depo-Provera)
Normalized name: DMPA
DrugBank: Zytron (DB11768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMPA (Depo-Provera) administered every 3 months
Study: 9437560
Drug: Microgynon administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microgynon administered monthly
Study: 26119653
Drug: Optimal Medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Medical Therapy (OMT) and revascularization
Study: 23773733
Drug: Fasudil (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasudil (0.9 mg/dL)
Study: 23773733
Drug: Papaverine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine (0.4 mg/mL mixed with heparinized blood)